Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients Characteristics
2.2. Pulmonary Function Tests
2.3. Image Acquisition
2.4. Dosimetry Evaluation
2.5. Evaluation of Thoracic HRCT Indication
- -
- Clinical deterioration (fever, desaturation);
- -
- Significant decrease in PFTs (at least 10% drop in FVC);
- -
- Monitoring for oncological purposes.
2.6. Statistical Analysis
3. Results
Patients’ Characteristics
4. Discussion
Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bradley, B. Interstitial Lung Disease Guideline: The British Thoracic Society in Collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008, 63, 1. [Google Scholar]
- Guiot, J. Clinical Experience in Idiopathic Pulmonary Fibrosis: A Retrospective Study. Acta Clin. Belg. 2018, 73, 139–143. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2013, 188, 733–748. [Google Scholar] [CrossRef]
- Raghu, G. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. [Google Scholar] [CrossRef]
- Raghu, G.; Remy-Jardin, M.; Richeldi, L.; Thomson, C.C.; Inoue, Y.; Johkoh, T.; Kreuter, M.; Lynch, D.A.; Maher, T.M.; Martinez, F.J.; et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022, 205, e18–e47. [Google Scholar] [CrossRef]
- Hilberg, O.; Hoffmann-Vold, A.-M.; Smith, V.; Bouros, D.; Kilpeläinen, M.; Guiot, J.; Morais, A.; Clemente, S.; Daniil, Z.; Papakosta, D.; et al. Epidemiology of Interstitial Lung Diseases and Their Progressive-Fibrosing Behaviour in Six European Countries. ERJ Open Res. 2022, 8, 00597–02021. [Google Scholar] [CrossRef]
- Latsi, P.I.; Du Bois, R.M.; Nicholson, A.G.; Colby, T.V.; Bisirtzoglou, D.; Nikolakopoulou, A.; Veeraraghavan, S.; Hansell, D.M.; Wells, A.U. Fibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends. Am. J. Respir. Crit. Care Med. 2003, 168, 531–537. [Google Scholar] [CrossRef]
- Guiot, J.; Moermans, C.; Henket, M.; Corhay, J.-L.; Louis, R. Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung 2017, 195, 273–280. [Google Scholar] [CrossRef] [PubMed]
- Bonhomme, O.; André, B.; Gester, F.; De Seny, D.; Moermans, C.; Struman, I.; Louis, R.; Malaise, M.; Guiot, J. Biomarkers in Systemic Sclerosis-Associated Interstitial Lung Disease: Review of the Literature. Rheumatology 2019, 58, 1534–1546. [Google Scholar] [CrossRef]
- Inoue, Y.; Kaner, R.J.; Guiot, J.; Maher, T.M.; Tomassetti, S.; Moiseev, S.; Kuwana, M.; Brown, K.K. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. Chest 2020, 158, 646–659. [Google Scholar] [CrossRef]
- Brauner, M.; Romdhane, H.B.; Brillet, P.-Y.; Freynet, O.; Dion, G.; Valeyre, D. Imagerie des pneumopathies infiltrantes diffuses. La Presse Médicale 2010, 39, 73–84. [Google Scholar] [CrossRef] [PubMed]
- Nasser, M.; Larrieu, S.; Si-Mohamed, S.; Ahmad, K.; Boussel, L.; Brevet, M.; Chalabreysse, L.; Fabre, C.; Marque, S.; Revel, D.; et al. Progressive Fibrosing Interstitial Lung Disease: A Clinical Cohort (the PROGRESS Study). Eur. Respir. J. 2021, 57, 2002718. [Google Scholar] [CrossRef] [PubMed]
- Cao, C.F.; Ma, K.L.; Shan, H.; Liu, T.F.; Zhao, S.Q.; Wan, Y.; Wang, H.Q. CT Scans and Cancer Risks: A Systematic Review and Dose-Response Meta-Analysis. BMC Cancer 2022, 22, 1238. [Google Scholar] [CrossRef]
- Campochiaro, C.; De Luca, G.; Lazzaroni, M.-G.; Armentaro, G.; Spinella, A.; Vigone, B.; Ruaro, B.; Stanziola, A.; Benfaremo, D.; De Lorenzis, E.; et al. Real-Life Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study. RMD Open 2023, 9, e002850. [Google Scholar] [CrossRef]
- Li, D.; Liu, X.; Huang, J.; Hang, W.; Yu, G.; Xu, Y. Impact of Antifibrotic Therapy on Disease Progression, All-Cause Mortality, and Risk of Acute Exacerbation in Non-IPF Fibrosing Interstitial Lung Diseases: Evidence from a Meta-Analysis of Randomized Controlled Trials and Prospective Controlled Studies. Ther. Adv. Respir. Dis. 2024, 18, 17534666241232561. [Google Scholar] [CrossRef] [PubMed]
- Wells, A.U. Forced Vital Capacity as a Primary End Point in Idiopathic Pulmonary Fibrosis Treatment Trials: Making a Silk Purse from a Sow’s Ear. Thorax 2013, 68, 309–310. [Google Scholar] [CrossRef]
- Paterniti, M.O.; Bi, Y.; Rekić, D.; Wang, Y.; Karimi-Shah, B.A.; Chowdhury, B.A. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals ATS 2017, 14, 1395–1402. [Google Scholar] [CrossRef] [PubMed]
- Christner, J.A.; Kofler, J.M.; McCollough, C.H. Estimating Effective Dose for CT Using Dose–Length Product Compared with Using Organ Doses: Consequences of Adopting International Commission on Radiological Protection Publication 103 or Dual-Energy Scanning. Am. J. Roentgenol. 2010, 194, 881–889. [Google Scholar] [CrossRef] [PubMed]
- Directorate-General for Research and Innovation (European Commission). In European Guidelines on Quality Criteria for Computed Tomography; Office for Official Publications of the European Communities: Luxembourg, 2000; ISBN 978-92-828-7478-3.
- Sarma, A.; Heilbrun, M.E.; Conner, K.E.; Stevens, S.M.; Woller, S.C.; Elliott, C.G. Radiation and Chest CT Scan Examinations. Chest 2012, 142, 750–760. [Google Scholar] [CrossRef]
- Kędzierski, B.; Macek, P.; Dziadkowiec-Macek, B.; Truszkiewicz, K.; Poręba, R.; Gać, P. Radiation Doses in Cardiovascular Computed Tomography. Life 2023, 13, 990. [Google Scholar] [CrossRef]
- MirDerikvand, A.; Bagherzadeh, S.; MohammadSharifi, A. Assessment and Comparison of Radiation Dose and Cancer Risk in Thoracic Diagnostic and Radiotherapy Treatment Planning CT Scans. J. Radiat. Res. Appl. Sci. 2023, 16, 100717. [Google Scholar] [CrossRef]
- Amis, E.S.; Butler, P.F.; Applegate, K.E.; Birnbaum, S.B.; Brateman, L.F.; Hevezi, J.M.; Mettler, F.A.; Morin, R.L.; Pentecost, M.J.; Smith, G.G.; et al. American College of Radiology White Paper on Radiation Dose in Medicine. J. Am. Coll. Radiol. 2007, 4, 272–284. [Google Scholar] [CrossRef] [PubMed]
- Miller, M.R. Standardisation of Spirometry. Eur. Respir. J. 2005, 26, 319–338. [Google Scholar] [CrossRef] [PubMed]
- Kreuter, M.; Polke, M.; Walsh, S.L.F.; Krisam, J.; Collard, H.R.; Chaudhuri, N.; Avdeev, S.; Behr, J.; Calligaro, G.; Corte, T.; et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: International Survey and Call for Harmonisation. Eur. Respir. J. 2020, 55, 1901760. [Google Scholar] [CrossRef]
- Raghu, G.; Nyberg, F.; Morgan, G. The Epidemiology of Interstitial Lung Disease and Its Association with Lung Cancer. Br. J. Cancer 2004, 91, S3–S10. [Google Scholar] [CrossRef]
- Gibson, G.J.; Loddenkemper, R.; Sibille, Y.; Lundback, B. The European Lung White Book: Respiratory Health and Disease in Europe, 2nd ed.; European Respiratory Society: Sheffield, UK, 2013; ISBN 978-1-84984-043-9. [Google Scholar]
- on behalf of the Trail Network; Solomon, J.J.; Danoff, S.K.; Goldberg, H.J.; Woodhead, F.; Kolb, M.; Chambers, D.C.; DiFranco, D.; Spino, C.; Haynes-Harp, S.; et al. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Adv. Ther. 2019, 36, 3279–3287. [Google Scholar] [CrossRef]
- Frix, A.-N.; Cousin, F.; Refaee, T.; Bottari, F.; Vaidyanathan, A.; Desir, C.; Vos, W.; Walsh, S.; Occhipinti, M.; Lovinfosse, P.; et al. Radiomics in Lung Diseases Imaging: State-of-the-Art for Clinicians. JPM 2021, 11, 602. [Google Scholar] [CrossRef] [PubMed]
- Guiot, J.; Vaidyanathan, A.; Deprez, L.; Zerka, F.; Danthine, D.; Frix, A.; Lambin, P.; Bottari, F.; Tsoutzidis, N.; Miraglio, B.; et al. A Review in Radiomics: Making Personalized Medicine a Reality via Routine Imaging. Med. Res. Rev. 2022, 42, 426–440. [Google Scholar] [CrossRef] [PubMed]
- Guiot, J.; Vaidyanathan, A.; Deprez, L.; Zerka, F.; Danthine, D.; Frix, A.-N.; Thys, M.; Henket, M.; Canivet, G.; Mathieu, S.; et al. Development and Validation of an Automated Radiomic CT Signature for Detecting COVID-19. Diagnostics 2020, 11, 41. [Google Scholar] [CrossRef]
- Cao, M.; Sheng, J.; Qiu, X.; Wang, D.; Wang, D.; Wang, Y.; Xiao, Y.; Cai, H. Acute Exacerbations of Fibrosing Interstitial Lung Disease Associated with Connective Tissue Diseases: A Population-Based Study. BMC Pulm. Med. 2019, 19, 215. [Google Scholar] [CrossRef]
- Jungblut, L.; Euler, A.; Von Spiczak, J.; Sartoretti, T.; Mergen, V.; Englmaier, V.; Landsmann, A.; Mihai, C.-M.; Distler, O.; Alkadhi, H.; et al. Potential of Photon-Counting Detector CT for Radiation Dose Reduction for the Assessment of Interstitial Lung Disease in Patients with Systemic Sclerosis. Investig. Radiol. 2022, 57, 773–779. [Google Scholar] [CrossRef] [PubMed]
- Gaillandre, Y.; Duhamel, A.; Flohr, T.; Faivre, J.-B.; Khung, S.; Hutt, A.; Felloni, P.; Remy, J.; Remy-Jardin, M. Ultra-High Resolution CT Imaging of Interstitial Lung Disease: Impact of Photon-Counting CT in 112 Patients. Eur. Radiol. 2023, 33, 5528–5539. [Google Scholar] [CrossRef] [PubMed]
- Abdo, A.; Karam, E.; Henry, T.; Leygnac, S.; Haioun, K.; Khalil, A.; Debray, M.-P. Radiation Dose Reduction with the Wide-Volume Scan Mode for Interstitial Lung Diseases. Eur. Radiol. 2021, 31, 7332–7341. [Google Scholar] [CrossRef] [PubMed]
- Sciensano. In Non-Communicable Diseases: Cancer; Health Status Report: Bruxelles, Belgium, 2023.
- Samet, J.M.; Wiggins, C.L.; Humble, C.G.; Pathak, D.R. Cigarette Smoking and Lung Cancer in New Mexico. Am. Rev. Respir. Dis. 1988, 137, 1110–1113. [Google Scholar] [CrossRef] [PubMed]
- Naccache, J.-M.; Gibiot, Q.; Monnet, I.; Antoine, M.; Wislez, M.; Chouaid, C.; Cadranel, J. Lung Cancer and Interstitial Lung Disease: A Literature Review. J. Thorac. Dis. 2018, 10, 3829–3844. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer Statistics, 2023. CA A Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef]
- Griffey, R.T.; Sodickson, A. Cumulative Radiation Exposure and Cancer Risk Estimates in Emergency Department Patients Undergoing Repeat or Multiple CT. Am. J. Roentgenol. 2009, 192, 887–892. [Google Scholar] [CrossRef]
- Rampinelli, C.; De Marco, P.; Origgi, D.; Maisonneuve, P.; Casiraghi, M.; Veronesi, G.; Spaggiari, L.; Bellomi, M. Exposure to Low Dose Computed Tomography for Lung Cancer Screening and Risk of Cancer: Secondary Analysis of Trial Data and Risk-Benefit Analysis. BMJ 2017, 356, j347. [Google Scholar] [CrossRef]
- Shao, Y.-H.; Tsai, K.; Kim, S.; Wu, Y.-J.; Demissie, K. Exposure to Tomographic Scans and Cancer Risks. JNCI Cancer Spectr. 2020, 4, pkz072. [Google Scholar] [CrossRef]
Justified Chest CT Scans | Non-Justified Chest CT Scans | |
---|---|---|
| Routine follow up | |
Justified a posteriori | Non-justified a posteriori | |
Incidental findings (e.g., lung nodule) | No incidental findings |
n = 129 | |
---|---|
Male n (%) | 79 (61.2%) |
Mean Age (±SD) | 63.7 (±2.3) |
Active smokers n (%) | 76 (58.9%) |
Mean follow-up in years (±SD) | 3.7 (±2.3) |
FVC ± SD (% predicted) | 81 (±19) |
FEV1 ± SD (% predicted) | 81(±20) |
DLCO ± SD (% predicted) | 54 (±20) |
KCO ± SD (% predicted) | 82 (±25) |
TLC ± SD (% predicted) | 77 (±17) |
Number of CT/patient | 6.34 ± 4.12 |
Low-dose CT/patient | 0.5 ± 1 |
% Low-dose CT/patient | 8 ± 18.5 |
Contrast CT scan/patient | 1 ± 2 |
% Contrast CT scan/patient | 17 ± 23 |
Emergency CT scan/patient | 0.5 ± 1 |
% Emergency CT scan/patient | 6.7 ± 31 |
% Justified emergency CT scan | 94.2 |
Number of routine CT scan | 5.6 ± 3.5 |
% Justification a priori of routine CT scan | 57 ± 32 |
% Justification a posteriori of routine CT scan | 60 ± 34 |
Number of CT scans | |
1 year | 2.6 ± 1.5 |
3 years | 4.5 ± 2.5 |
On the overall follow-up | 6.4 ± 4.1 |
Number of mean CT scans/patient/year | 1.7 ± 0.4 |
Irradiation CDTI (mGy)/patient | |
1 year | 27.3 ± 20.2 |
3 years | 54.5 ± 64.9 |
On the overall follow-up | 67.8 ± 52.2 |
Irradiation DLP (mGy*cm)/patient | |
1 year | 897 ± 595 |
3 years | 1582 ± 908 |
On the overall follow-up | 2192 ± 1474 |
Irradiation in CDTI (mGy)/year | 34.9 ± 64.9 |
Irradiation in DLP (mGy*cm)/year | 1095 ± 1971 |
Drop of DLCO < 15% | Drop of DLCO ≥ 15% | ||
---|---|---|---|
Median (IQR) | Median (IQR) | p Values | |
Age | 61 (52–71) | 66 (53–75) | 0.127779 |
Follow up (month) | 44 (22–60) | 49 (38–71) | 0.040146 |
Contrast CT scan | 0 (0–1) | 1 (0–2) | 0.009261 |
% justification a priori of emergency CT scan 1 | 100 (100–100) | 100 (100–100) | 0.704275 |
% justification a priori of routine CT scan | 50 (30–71) | 50 (33–80) | 0.600688 |
% justification a posteriori of routine CT scan | 50 (33–80) | 50 (33–80) | 0.978767 |
irradiation over 1 year CTDI (mGy) | 28 (16–40) | 26 (17–39) | 0.676711 |
irradiation over 1 year PDL (mGy*cm) | 793 (394–1111) | 700 (554–1174) | 0.742729 |
irradiation over 3 years CTDI (mGy) | 42 (27–65) | 58 (39–75) | 0.039473 |
irradiation over 3 years DLP (mGy*cm) | 1352 (973–2204) | 1585 (1254–2466) | 0.057749 |
Total irradiation CDTI (mGy) | 56 (30–85) | 78 (47–103) | 0.004655 |
Total irradiation DLP (mGy*cm) | 1840 (1050–2641) | 2431 (1613–3266) | 0.021919 |
irradiation/year CDTI (mGy/year) | 17 (10–29) | 18 (12–24) | 0.815285 |
Irradiation/year (mGy*cm/year) | 692 ± 536 | 831 ± 799 | 0.787854 |
% low-dose CT scan | 0 (0–14) | 0 (0–6.7) | 0.236869 |
% contrast CT Scan | 0 (0–20) | 17 (0–33) | 0.031569 |
% emergency CT scan | 0 (0–11) | 0 (0–14) | 0.360847 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Berg, J.; Frix, A.-N.; Henket, M.; Gester, F.; Winandy, M.; Canivet, P.; Njock, M.-S.; Thys, M.; Desir, C.; Meunier, P.; et al. Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs. Diagnostics 2024, 14, 2136. https://doi.org/10.3390/diagnostics14192136
Berg J, Frix A-N, Henket M, Gester F, Winandy M, Canivet P, Njock M-S, Thys M, Desir C, Meunier P, et al. Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs. Diagnostics. 2024; 14(19):2136. https://doi.org/10.3390/diagnostics14192136
Chicago/Turabian StyleBerg, Julien, Anne-Noelle Frix, Monique Henket, Fanny Gester, Marie Winandy, Perrine Canivet, Makon-Sébastien Njock, Marie Thys, Colin Desir, Paul Meunier, and et al. 2024. "Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs" Diagnostics 14, no. 19: 2136. https://doi.org/10.3390/diagnostics14192136